Trial Profile
A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- Acronyms The CAPTAIN Trial
- Sponsors EVER Neuro Pharma
- 24 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 17 Apr 2015 New trial record